Abstract
e17620 Background: In collaboration with the FDA, the Critical Path Institute - PRO Consortium NSCLC WG is developing a new PRO measure to assess treatment (tx) benefit in advanced NSCLC trials and...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
